IPO Profile: Regenxbio Inc

Company Details

Rockville, Md.

240-552-8181

regenxbio.com

Description: REGENXBIO Inc, formerly ReGenX Biosciences, LLC, is a biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company’s AAV gene delivery platform (its NAV technology platform) consists of exclusive rights to over 100 AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors). The company focuses on the lives of patients suffering from diseases with unmet medical needs by developing and commercializing gene therapy products administered directly into the body, or in vivo, based on its NAV technology platform. Its NAV technology platform is applied in the development of over 20 product candidates for a range of diseases, including five product candidates and approximately 20 partnered product candidates developed by its NAV technology licensees. The company’s products candidates include RGX-501, RGX-111, RGX-121, RGX-314 and RGX-321.

IPO Details

Exchange and Ticker: Nasdaq: RGNX

Filing Range: 5.56 million shares @ $22 to $22

Offering Price: $22

Closing price as of 9/17/15: $30:45

Offering Size: $138.6 million

Shares Outstanding: 26.3 million

Underwriters: Morgan Stanley & Co, Merrill Lynch Pierce Fenner, Piper Jaffray Cos

Co-manager: Chardan Capital Markets LLC

Company Counsel: Gunderson Dettmer Stough Villeneuve Franklin&Hachi

Manager Counsel: Davis Polk & Wardwell

Auditor: PricewaterhouseCoopers LLP

Market Capitalization on 9/30.15: $579.29 million

Closing price at current month end: $22.03

Investment Details

Backers

• Fidelity Biosciences
• Deerfield Management Company LP
• Venrock Inc
• Brookside International
• Foresite Capital Management LLC
• Sectoral Asset Management Inc

Financing Rounds

Date Amount Valuation

• 10/31/13 $7.9M n/a
• 1/23/15 $27.5M n/a
• 5/15/15 $70.5M n/a

Total funding raised: $105.9 million

IPO Profile: Penumbra Inc

Company Details

Alameda, Calif.

510-748-3200

www.penumbrainc.com

Description: Penumbra Inc is an interventional therapies company that designs, develops, manufactures and markets medical devices. The company has a portfolio of products that addresses medical conditions and clinical needs across two markets, which includes neuro and peripheral vascular. Its neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. The company’s neuro surgical tools include Apollo System. Its peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device (POD) and Indigo System. Its products address conditions, which include ischemic stroke and hemorrhagic stroke, which involve blockage or rupture of blood vessels in the brain and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures, which involve the use of medical devices to remove or treat blockages or ruptures of blood vessels.

IPO Details

Exchange and Ticker: NYSE: PEN

Filing Range: 3.8 million shares @ $25 to $28

Offering Price: $30

Closing price as of 9/18/15: $41.30

Offering Size: $120 million

Shares Outstanding: 30.6 million

Underwriters: JP Morgan, Merrill Lynch Pierce Fenner

Co-managers: Wells Fargo Securities LLC, Canaccord Genuity

Company Counsel: Davis Polk & Wardwell

Manager Counsel: Goodwin Procter LLP

Auditor: Deloitte & Touche LLP

Market Capitalization on 9/30/15: $1228.61 million

Closing price as of 9/30/15: $40.10

Investment Details

Backers

• Angels’ Forum & the Halo Fund
• Fidelity Investments

Financing Rounds

Date Amount Valuation

• 12/21/04 $7M n/a
• 3/9/07 $1.34M $75M
• 2/4/08 $20M $140M
• 10/31/12 $121K n/a
• 5/16/14 $60M n/a

Total funding raised: $88.47 million

IPO Profile: Nabriva Therapeutics AG

Company Details

Vienna, Austria

431-740-930

www.nabriva.com

Description: Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Two plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs). In addition, the company has completed a Phase Two clinical trial for acute bacterial skin and skin structure infections (ABSSSI) and in Discovery Phase development of extended-spectrum pleuromutilins (ESPs), a pleuromutilin compound that treats Gram-negative bacteria. The company is a spin-off of Sandoz GmbH and receives investment from HBM Healthcare Investments, Novartis Venture Fund, Omega Funds, OrbiMed Healthcare Fund Management, Phase4 Partners, Vivo Capital and the Wellcome Trust.

Competition: Cempra Inc, Actavis PLC, Melinta Therapeutics, Paratek Pharamceuticals Inc.

IPO Details

Exchange and Ticker: Nasdaq: NBRV

Filing Range: 9 million shares @ $10.50 to $10.50

Offering Price: $10.25

Closing price as of 9/18/15: $13.24

Offering Size: $92.3 million

Shares Outstanding: 11.4 million

Underwriters: Leerink Partners LLC, RBC Capital Markets

Co-managers: Needham & Co LLC, Wedbush Securities

Company Counsel: Wilmer Cutler & Pickering

Manager Counsel: Covington & Burling

Auditor: PricewaterhouseCoopers LLP

Market Capitalization on 9/30/15: $108.43 million

Closing price at current month end: $9.50

Investment Details

Backers

• HBM Healthcare Investments AG
• Novartis Venture Funds
• Global Life Science Ventures GmbH
• Phase4 Ventures Ltd
• OrbiMed Advisors LLC
• EcoR1 Capital LLC
• Tavistock Group Inc
• Vivo Capital LLC
• Nomura International plc

Financing Rounds

Date Amount Valuation

• 1/31/06 $50.8M n/a
• 11/7/07 n/a n/a
• 9/30/09 $10.6M n/a
• 10/28/09 $11.3M n/a
• 4/7/15 $120M n/a

Total funding raised: $192.84 million

Source: Based on data from Thomson Reuters.

Photo illustration from Shutterstock.